IGC Pharma, Inc. (IGC) is a clinical-stage biotechnology company that leverages artificial intelligence (AI) to develop treatments for Alzheimer's disease and other neurological and metabolic disorders. The company's main focus is on creating innovative, cannabinoid-based therapies. Here are some key details about the company: Pipeline and Technology IGC-AD1: This is the company's lead drug candidate. It's a cannabinoid-based therapy in a Phase 2 clinical trial (CALMA) for the treatment of agitation in dementia due to Alzheimer's. Preclinical research has also shown its potential to reduce amyloid plaques and neurofibrillary tangles, which are hallmarks of the disease. Other Drug Candidates: IGC has several other assets in its pipeline, including: TGR-63: A preclinical-stage drug candidate that has shown promise in reducing neurotoxicity in Alzheimer's cell lines and in crossing the blood-brain barrier. IGC-M3: A preclinical-stage molecule that targets multiple biological mechanisms of Alzheimer's, including amyloid aggregation and neuroinflammation. IGC-1C: An early-stage program focused on tau protein and neurofibrillary tangles. IGC-1A: Identified through AI modeling as a potential GLP-1 agonist, opening new avenues in metabolic and neurological treatment. AI Integration: IGC Pharma is at the forefront of integrating AI into its research and development. It has developed MINT-AD, an AI-powered diagnostic platform designed to predict Alzheimer's risk and aid in early detection. This platform uses various data sources, including brain scans, genetics, and cognitive metrics, to create risk profiles. Financials and Stock Information Stock Symbol: IGC Exchange: NYSE American Market Cap: Approximately $29-33 million Recent Performance: The company has reported recent earnings that beat analyst estimates. However, the stock has experienced significant volatility and is currently trading at a low price point. Other Ventures In addition to its pharmaceutical pipeline, IGC also has a business segment that includes a family of cannabidiol (CBD)-based consumer products under the brand Holiby, which targets women's wellness and sleep aids. The company also previously had an infrastructure business segment.